GSKMEX:GSKN 73 EV-to-FCF is 18.33 as of Jun. 24, 2026, which is 12% above its 10-year median of 16.41. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 562 Drug Manufacturers companies, GSK ranks better than 51.42% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GSK's Enterprise Value is MXN2,156,867 Mil.
GSK's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN117,654 Mil. Therefore, GSK's EV-to-FCF for today is 18.33.
The historical rank and industry rank for GSK's EV-to-FCF or its related term are showing as below:
MEX:GSKN'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.42 Med: 16.41 Max: 56.46
Current: 19.68
During the past 13 years, the highest EV-to-FCF of GSK was 56.46. The lowest was 9.42. And the median was 16.41.
MEX:GSKN's EV-to-FCF is ranked better than 51.42% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs MEX:GSKN: 19.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-24), GSK's stock price is MXN901.11.
GSK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN70.374. Therefore, GSK's PE Ratio (TTM) for today is 12.80.
GSK (MEX:GSKN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GSK's share price for today is MXN901.11.
GSK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN70.374.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GSK EV-to-FCF Related Terms
GSK EV-to-FCF Historical Data
* Premium members only.
The historical data trend for GSK's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GSK's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GSK's EV-to-FCF falls into.
GSK's current Enterprise Value is MXN2,156,867 Mil.
GSK's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN117,654 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (MEX:GSKN) has a EV-to-FCF of 18.33 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GSK and its competitors. This is 12% above median its historical median of 16.41. Over the past decade, GSK's EV-to-FCF has ranged from 9.42 to 56.46. According to the industry distribution chart, GSK ranks #273 out of 562 companies in the Drug Manufacturers industry, placing it in the top 48.6%.
Is GSK's EV-to-FCF too high?
GSK's current EV-to-FCF of 18.33 is 12% above median its 10-year median of 16.41. Over the past 10 years, this metric has ranged from a low of 9.42 to a high of 56.46. The Drug Manufacturers industry median EV-to-FCF is 20.11. GSK's value of 18.33 is 8.9% below this industry median. Based on the distribution chart, GSK ranks #273 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #273 out of 562 companies for EV-to-FCF. This puts GSK in the upper half of its industry. The industry median EV-to-FCF is 20.11. GSK's value of 18.33 is 8.9% below this benchmark. Historically, GSK's own EV-to-FCF has ranged from 9.42 to 56.46 over the past decade. While the company's 10-year median is 16.41 vs. the industry median of 20.11, GSK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current EV-to-FCF of 18.33 is 8.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current EV-to-FCF is 18.33, which is 12% above median its own 10-year median of 16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current EV-to-FCF is 18.33, which is 12% above median its 10-year median of 16.41 and 8.9% below the Drug Manufacturers industry median of 20.11. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For GSK (MEX:GSKN), the current EV-to-FCF is 18.33 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (MEX:GSKN) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82.
GuruFocus considers GSK to be Fairly Valued.
Key valuation signals for MEX:GSKN:
EV-to-FCF: 18.33 (12% above median its 10-year median of 16.41)
GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
Industry Position: 8.9% below the Drug Manufacturers median (#273 of 562)
No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score
Get the complete analysis for MEX:GSKN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GSKN has been successfully added to your 
